Eczema is a common disease affecting up to 20% of children and approximately 3% of adults, with a drugs market estimated up to 75 BSEK worldwide. The intense itch associated with the condition can lead to sleeping disorders, anxiety and depression. There is no cure as of today. The current treatments can ameliorate the symptoms…. Read more »
- TIRmed Pharma raises 5.4 MSEK in equity to continue pursuing preclinical development of new antiviral treatment and a topical treatment for atopic eczema.
- New publication
- TIRmed Pharma receives approval to grant patents in Europe
- TIRmed Pharma receives approval of patent in the US
- TIRmed Pharma receives SME Instrument Phase 1 grant from EU Grant No 885787-TIR-C